Shares of CRO concept stocks are leading gains in Hong Kong trading. As of writing, WUXI APPTEC (02359) has surged 11.05% to HKD 180.9, GENSCRIPT BIO (01548) is up 10.18% to HKD 17.96, ASYMCHEM (06821) has risen 7.71% to HKD 117.4, and WUXI BIO (02269) is trading 3.92% higher at HKD 40.34.

On the news front, WUXI APPTEC announced that its first-half revenue reached RMB 28.897 billion, a year-on-year increase of 38.93%, with net profit attributable to shareholders hitting RMB 11.08 billion, up 29.43% from the same period last year. The company has also raised its full-year 2026 performance guidance, lifting its overall revenue forecast from RMB 51.3 billion to RMB 53 billion to a new range of RMB 58.5 billion to RMB 60.5 billion, and its revenue growth rate for continuing operations from 18% to 22% to between 35% and 39%.

Notably, several overseas MNCs and CXO firms have recently disclosed interim profit warnings and raised their full-year guidance. Zhongtai Securities stated that demand is gradually improving, with the pro-cyclical recovery logic continuing to play out, and Q2 performance is expected to remain strong. As the financing environment for overseas biotech firms marginally improves, and as China's innovative drug BD transactions continue to materialize along with the gradual launch of commercial projects, the industry's order volume is expected to see a rebound.